Downsizing: Biotech Companies Are Catching Up to Big Pharma
For the past year or so, I have been focusing on the downsizing and layoffs taking place at big pharmaceutical companies. The unprecedented size and scope of these massive layoffs have overshadowed the downsizing and job loss taking place at small to mid-size public and private biopharmaceutical companies. In contrast with most fully-integrated vertical pharmaceutical companies that are flush with cash, most biotech companies—even the likes of Amgen, Genentech, Gilead and others—don’t have the cash reserves to maintain operations in a down economy or when a drug candidate fails in clinical development. This coupled with the lack of venture and private equity capital has been causing biopharmaceutical employees to lose sleep in recent months.
Over the past few days, two CA-based biopharmaceutical companies announced major layoffs. The first, San Jose-based Xenoport, announced that it plans on cutting its 222 person workforce by 50% over the next few months. According to company executives, the layoffs are necessary because the US Food and Drug Administration (FDA) failed to grant approval to its lead drug candidate Horizant, a treatment for restless leg syndrome. This will allow the company to annually save about $15.6 million and focus its development efforts on other products that are in Phase II clinical development.
San Francisco-based Exelixis today announced that it would cut about 40% of its workforce or 270 employees to focus on development of its late stage drug candidates. The biotechnology company, which expects to reduce its 2011 cash expenditures by about $90 million, said it would focus on the development of its anti-cancer drugs XL184, XL147 and XL765. These layoffs are occurring less than a year after the company announced a potential $1.0 billion deal with Sanofi-Aventis in which Sanofi invested $140 million upfront to license two of its oncology drug candidates.
Things are also not going well for the numerous small to midsize biotechnology companies in the Seattle area. According to Xconomy, a company that tracks layoffs in and around Seattle, the region has shed 4,500 biopharmaceutical industry jobs since 2008.
Finally, BNET compiled a top biotech layoff list for 2009. The notables that made the list are shown below.
- Sepracor (530). The layoffs represented 20 percent of Sepracor’s workforce, and another 410 contract sales reps also got the axe. The restructuring apparently worked and Dainippon Sumitomo Pharma the company later in 2009.
- Allergan (460). This represented a five percent reduction in the company’s workforce.
- Genmab (300). Arzerra (ofatumumab) the company’s leukemia drug won FDA approval a week before layoffs were announced (go figure). But Genmab wanted to cut manufacturing and late-stage clinical work to refocus on antibody discovery.
- Oscient Pharmaceuticals (280). Oscient cut about 100 jobs in February, 2009 to entice acquisition partners. When that didn’t work, the firm cut another 180 in June as it dumped the sales force for its two marketed products. Cornerstone Therapeutics later picked up Oscient’s antibiotic Factive during bankruptcy.
- Amylin Pharmaceuticals (200). After cutting 340 jobs at the end of 2008 amid declining diabetes drug sales and regulatory delays, Amylin eliminated 200 sales reps in mid-2009.
While these represent the largest layoffs that occurred in 2009, thousands of other biopharmaceutical employees also lost their jobs. If the life sciences sector is the part of the economy that has been relatively unscathed during the economic downturn, imagine what life must be like for employees in other sectors that have been hard hit!
Until next time...
Good Luck and Good Job Hunting ????
Ed Silverman, who runs the
pharmaceutical industry and seemingly getting tougher.
, or 12 percent of its work force, by 2014 to cut costs as it reported disappointing fourth quarter earnings. The job cuts will be made across all regions and divisions and were necessary because some of the company’s major products including the child asthma medication Pulmicort, which made sales of $1.3 billion in 2009, and breast cancer treatment Arimidex, with $1.92 billion in sales will be losing patent protection in the near future.
Healthcare informatics (HCI) is one of the fastest growing professions in the US. This is because the Obama administration has allocated billions of stimulus dollars to create electronic healthcare records (EHR) in an attempt to reduce healthcare costs.
I have heard from many jobseekers, who—despite many years of work experience— are having difficulty finding full time employment. During economic down turns many companies cannot or are reluctant to hire full time employees. However, this doesn’t mean that there is work to be done. Consequently, many firms look for part-time, temporary or contract workers to handle the work that must get done to maintain operations.
The whole world is atwitter about Twitter (pun intended). One of the reasons why social media tools like Twitter are so effective is that information can reach very large audiences almost instantaneously.
Do you ever wonder whether or not you are getting paid enough at work or what the person sitting next to you makes? I bet most employees think about this from time to time—especially around bonus time. This isn’t surprising because salaries are one of the best kept secrets at most companies and organizations. Keeping salaries under wraps is good for morale mostly because it minimizes resentment among employees However, because nobody really knows how their salaries match up with their co-workers, determining what constitutes an acceptable salary can become problematic for jobseekers and long time employees. Not to worry—Monster.com has created
Reuters reports
Everybody who works for a living has to learn how to deal with annoying co-workers who, either directly or indirectly, may have an effect on your career trajectory. However, we are living in uncertain financial times, when having a job--no matter the circumstances--is more important than personal happiness on a day-to-day basis. Nevertheless, office politics are a reality regardless of how good or bad the economy is. To that end, managing difficult co-workers is essential if you want to learn how to adroitly deal with workplace politics sand advance your own career.
The debate, if you can call it that, over whether or not interactive social media platforms like
There is a growing worldwide shortage of nurses and other typically female-dominated medical professionals. The acute shortage of nurses in Europe has induced at least one Czechoslovakian clinic to develop a novel—albeit somewhat controversial— approach to retain and recruit hospital personnel. According to an
The advent of social networking sites like MySpace, Facebook and Linked In have been a boon to recruiters and human resources (HR) professionals. Social networks represent a vast and easily-accessible source of job candidates whose professional credentials and personal information are readily available to determine whether or not they may be potential new hires. While the effectiveness of recruiters and HR professionals to source new talent is debatable, I contend that there is nobody more qualified than employees at a company to identify prospective new employees who may bring value to an organization. A number of forward-thinking companies have realized that the best way to find “right fit job candidates” is to mine the social networking contacts of their existing employees. To that end,
Over the past three years, more than
While I have never been layed off, I understand how awful and painful it must be. After all, unlike people who were fired for cause or otherwise, most people who are layed off are performing well but they simply became too expensive or expendable to remain with a company facing financial exigency.
According to a
Astra Zeneca announced today that it would cut 1400 jobs and close several manufacturing facilities worldwide.
Last month, 240,000 American workers lost their jobs. Many of these jobs were lost as a result of corporate lay offs and restructuring—things that are likely to continue as we attempt to navigate a course through these financially troubling times. Unlike being fired, lay offs and job losses that result from restructuring have little to do with individual job performances and everything to do with budget constraints and reductions. That said how should a person who is laid off from a job deal with it on a resume when looking for a new job? I found a
Millennium employees find themselves in an enviable position that most pharmaceutical and biotechnology employee would die for! Shortly after Takeda announced that it would buy Cambridge MA-based Millennium Pharmaceuticals for $8.8 billion, 


